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Abstract
Background: IgE-mediated sensitization may be epigenetically programmed in utero, but early childhood environment
may further alter complex traits and disease phenotypes through epigenetic plasticity. However, the epigenomic
footprint underpinning IgE-mediated type-I hypersensitivity has not been well-understood, especially under a
longitudinal early-childhood life-course framework.
Methods: We used epigenome-wide DNA methylation (IlluminaHumanMethylation450 BeadChip) in cord blood and
mid-childhood peripheral blood to investigate pre- and post-natal methylation marks associated with mid-childhood
(age 6.7–10.2) total serum IgE levels in 217 mother-child pairs in Project Viva—a prospective longitudinal pre-birth
cohort in eastern Massachusetts, USA. We identified methylation sites associated with IgE using covariate-adjusted
robust linear regressions.
Results: Nineteen methylation marks in cord blood were associated with IgE in mid-childhood (FDR < 0.05) in genes
implicated in cell signaling, growth, and development. Among these, two methylation sites (C7orf50, ZAR1) remained
robust after the adjustment for the change in DNA methylation from birth to mid-childhood (FDR < 0.05). An analysis
of the change in methylation between cord blood and mid-childhood DNA (Δ-DNAm) identified 395 methylation
marks in 272 genes associated with mid-childhood IgE (FDR < 0.05), with multiple sites located within ACOT7 (4 sites),
EPX (5 sites), EVL (3 sites), KSR1 (4 sites), ZFPM1 (3 sites), and ZNF862 (3 sites). Several of these methylation loci were
previously associated with asthma (ADAM19, EPX, IL4, IL5RA, and PRG2).
Conclusion: This study identified fetally programmed and mid-childhood methylation signals associated with mid-
childhood IgE. Epigenetic priming during fetal development and early childhood likely plays an important role in IgE-
mediated type-I hypersensitivity.
Keywords: Epigenome-wide association studies, Total serum IgE, Life course analysis
Background
Immunoglobulin E (IgE)—a central mediator for type I
hypersensitivity—contributes to the pathogenesis of a wide
range of childhood-onset allergic diseases, including
asthma, allergic rhinitis, atopic dermatitis, and food allergy
[1–4]. IgE-mediated allergic sensitization has its roots very
early in life and is likely impacted by the in utero
environment [5, 6]. The manifestation of IgE-mediated re-
sponses often involves childhood re-exposures to antigens
in sensitized individuals, with subsequent IgE-dependent
release of inflammatory mediators that give rise to allergic
symptoms [3, 4].
To date, the most commonly used therapies for IgE-
mediated allergic responses in children focus on acute
and chronic symptom relief [7]; no treatment targets
the natural history of allergy pathogenesis across the
life course. Understanding the molecular origins and
mechanisms of IgE-mediated allergic responses, and
the plasticity of the associated molecular markers,
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would inform more effective screening, prevention, and
treatment strategies.
Epigenetic regulatory elements, such as DNA methyla-
tion marks, undergo dynamic reprogramming during em-
bryogenesis [8, 9]. The establishment of the human
methylome during fetal development coincides with early
immune development relevant to IgE-mediated allergic
sensitization and makes DNA methylation in cord blood a
potential early molecular marker of IgE-mediated disease
onset. DNA methylation patterns may vary after birth to
reflect the complex interplay between genetics, develop-
ment and maturation, and environmental exposures.
Therefore, plasticity of DNA methylation from birth may
portend the development and progression of diseases that
were driven by both genetic endowment and the environ-
ment, such as IgE-mediated allergic phenotypes during
childhood.
Previous studies have reported differential DNA methy-
lation in peripheral blood associated with total serum IgE
measures [10–13]. However, these studies were either
cross-sectional or case-control studies; the lack of pro-
spective nature of these studies impedes the identification
of epigenetic marks that predict development of allergy.
Further, most of these studies were conducted in later
childhood and adulthood. Since IgE-mediated allergic re-
sponses may have a fetal origin, these studies may not cap-
ture alterations during critical developmental windows, e.
g., the period of fetal immune development during which
IgE-dependent predisposition may originate.
To better understand the molecular origins and pro-
gression of IgE-mediated responses, we sought to
conceptualize the association between epigenome-wide
differential methylation in DNA from blood cells and
serum IgE measures using a life course framework [14]
(Fig. 1). Specifically, we used methylation data from
DNA from blood cells at two distinct time points—birth
and mid-childhood (mean age = 7.8 years)—to quantify
and dissect the influence of prenatal and childhood fac-
tors on IgE. We hypothesize that (1) epigenetic marks in
cord blood DNA reflecting the prenatal environment
serve as early markers of IgE-mediated allergic response
susceptibility in childhood, (2) some epigenetic marks
established at birth may be associated with IgE levels in
childhood independent of factors operating postnatally,
and (3) childhood environmental influences—captured
by changes in DNA methylation levels between cord
blood and mid-childhood peripheral blood—reflect the




Our study population is drawn from Project Viva—a pro-
spective longitudinal pre-birth cohort from Massachusetts,
USA. All participants were recruited at their initial obstet-
ric visit at Atrius Harvard Vanguard Medical Associates
from 1999 to 2002. Eligible participants were those with
single gestation, gestational age < 22 weeks at enrollment,
able to answer questions in English, and intended to stay
in the study region before delivery. A detailed cohort pro-
file has been published previously [13]. At enrollment,
mothers provided information on age at enrollment,
smoking habits (never smoker/former smoker/smoked
during pregnancy), education level, and familial atopy his-
tory of asthma, eczema, or hay fever. We collected date of
birth and sex from hospital records and calculated gesta-
tional age at birth as previously described [13]. Trained re-
search assistants conducted in-person research visits with
mother-child pairs in the hospital following delivery, in
early childhood (mean age = 3.3 years), and mid-childhood
(mean age = 7.8 years). Mothers reported child race/ethni-
city in early childhood.
Of the original 2128 mother-child pairs in the co-
hort, 616 children had mid-childhood plasma total IgE
measures. Among those, 242 children had cord blood
DNA methylation measurements at birth, 68 had per-
ipheral blood DNA methylation measurement at early
childhood, and 411 had peripheral blood DNA methy-
lation measurements at mid-childhood. Two hundred
and seventeen children had DNA methylation mea-
surements at both birth and mid-childhood, while 56
had DNA methylation measurements at all three time
points (at birth, early childhood, and mid-childhood)
(Fig. 2).
DNA methylation measures
Trained personnel collected blood samples at birth (umbil-
ical cord blood) and early and mid-childhood (peripheral
blood). DNA was extracted using the Qiagen Puregene Kit
(Valencia, CA) and bisulfite converted using the EZ DNA
Methylation-Gold Kit (Zymo Research, Irvine, CA). Sam-
ples were allocated to chips and plates using a two-stage
randomization algorithm and analyzed with Infinium
HumanMethylation450 BeadChip (Illumina, San Diego,
CA), which includes ~ 485,000 CpG sites at a single nu-
cleotide resolution. In the quality control step, we removed
technical replicates, samples with low quality, genotype
mismatch, and sex mismatch. At the probe level, low-
quality probes with detection P values > 0.05, probes on
sex chromosomes, SNP-associated probes, non-CpG
probes, and non-specific and previously identified cross-
reactive probes were excluded [15]. We further removed
probes within 10 base pairs of a known SNP (UCSC Hu-
man Feb. 2009 [GRCh37/hg19] Assembly) with a minor
allele frequency (MAF) ≥ 1%. After the quality control, a
total of 343,208 probes were included for subsequent ana-
lysis. We used the normal-exponential out-of-band
(“noob”) method for background correction and dye bias
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adjustment [16] and normalized our sample with Beta
Mixture Quantile Dilation (BMIQ) [17]. To control for
technical variability across sample plates, we applied Com-
bat [18]. We report the percent of methylation for each
CpG sites as β values, calculated as the signal intensity of
methylated cytosines over the signal intensity of methyl-
ated and un-methylated cytosines at the 5C position [β
value =M/(M +U)]. In order to control for cell-type het-
erogeneity, we applied ReFACTor—a reference-free
method based on principle component analysis (PCA)
with low rank approximation [19]. We chose this method
because ReFACTor components correlate well with mea-
sured eosinophil and neutrophil counts [19]. Eosinophils
and neutrophils are central effector immune cells that
often associate with allergic outcomes. By adequately
adjusting for eosinophil and neutrophil counts, we aimed
to reduce the influence of changes in eosinophil and neu-
trophil cellular composition. We computed the first five
ReFACTor components in cord blood and the first five
ReFACTor components in mid-childhood peripheral
blood, and used them in subsequent analysis for the ad-
justment of cell type composition.
Fig. 1 Conceptural model of the lifecourse framework. Path (a): epigenetic modifications established at birth may be associated with IgE levels in
childhood independent of factors operating postnatally; path (b): epigenetic marks established at birth may be further influenced by postnatal
experiences and exposures; and path (c): postnatal experiences and exposures may be associated with IgE levels independent of prenatal factors
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Total serum IgE measures
Total serum IgE concentrations were measured in mid-
childhood blood using ImmunoCAP (Phadia, Uppsala,
Sweden)—a widely used in vitro sandwich immunoassay
to quantitatively measure circulating IgE in serum
samples.
Statistical analyses
Cord blood DNA methylation and childhood total serum IgE
We evaluated the association of DNA methylation at each
individual CpG site in cord blood with total serum IgE
measured in mid-childhood using robust linear regression.
To remove the influence of extreme methylation outliers,
we restricted the methylation values between [25th
percentile − 3*IQR] and [75th percentile + 3*IQR], where
IQR represents interquantile range. Total serum IgE was
natural log-transformed, and model estimates are
expressed as the change in the log total serum IgE per 1%
increase in methylation values. Regression models were
adjusted for the following covariates selected a priori: ma-
ternal [age at enrollment (continuous), smoking status
(never, former, or during pregnancy), college graduate
(yes/no), maternal atopy history (yes/no)], child [sex (fe-
male/male), race/ethnicity (white/black/others), gesta-
tional age at birth (continuous), age at blood drawn
(continuous)], and the first five ReFACTor components
computed from cord blood to capture cellular heterogen-
eity [19]. A methylation site was considered to be
Fig. 2 Study flow chart
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epigenome-wide significant if it reached the false discovery
rate (FDR)-corrected p value of less than 0.05 based on
the method of Benjamini and Hochberg [20]. Additional
methylation signals, which were marginally significant
(FDR < 0.1), are included in the supplement. The main re-
gression model took the general form:
log IgEð Þ ¼ α0 þ α1CpG cbi þ α2X2 þ…þ αpXp
þ ε Model 1ð Þ
where α0 to the intercept for the population mean, α2X2
… αpXp to the covariates we selected a priori, α1CpG_cbi
correspond to ith methylation site in cord blood; ε is the
model error term.
Life course analysis
Under the “developmental origins of health and disease”
(DOHaD) framework [21], epigenetic endowment from
the in utero environment may set the health trajectory
of a developing fetus. Hence, some epigenetic marks
established at birth may act independently of factors op-
erating after birth and associate with mid-childhood
serum IgE. To identify CpG sites that are differentially
methylated at birth and not further modified postnatally
in our cohort, we considered the following model:
log IgEð Þ ¼ β0 þ β1CpG cbi þ β2ΔCpGi þ β3X3 þ…
þ βpXp þ η Model 2ð Þ
where β0 is the intercept for the population mean, β3X3
… βpXp to the baseline covariates we selected a priori, β1
CpG_cbi to the ith methylation site in cord blood mea-
sured at birth/baseline, and β2ΔCpGi corresponds to the
difference in DNA methylation at the ith CpG site be-
tween cord blood and peripheral blood (CpG_midchild-
hoodi – CpG_cbi) measured in mid-childhood; η is the
model error term.
If we frame this model in the context of a mediation
analysis, the term CpG_cbi is the direct effect of cord
blood methylation on IgE independently of postnatal
change in methylation levels. We considered a methyla-
tion site to be “early programmed” if CpG_cbi reached
epigenome-wide significance; a methylation site to cap-
ture postnatal environment and experiences if ΔCpGi
reached epigenome-wide significance; and a methylation
site to be associated with both prenatal (CpG_cbi) and
postnatal exposure (ΔCpGi) if both terms remained
epigenome-wide significant.
Sensitivity analysis
As a sensitivity analysis, we additionally adjusted for
current asthma status at mid-childhood (yes/no) to exam-
ine whether the adjustment for asthma would influence
our results. We additionally adjusted for asthma status in
mid-childhood because (1) children with asthma may have
higher total serum IgE levels compared to non-asthmatic
children and (2) children maybe on asthma medication
upon diagnosis, which leads to lowered serum IgE levels;
for both reasons, asthma status maybe a predictor of our
outcome—total serum IgE levels. On the other hand, we
did not adjust for other atopic diseases (food allergy and
eczema) because both of those variables showed high de-
gree of concordance with asthma (chi-square test p values
were both 0.0003). Including highly correlated variables
may result in multi-collinearity and decrease model stabil-
ity. Hence, we only adjust for asthma, a prevalence atopic
phenotype in mid-childhood in our dataset (prevalence =
21.7%). We further stratified our analysis by child race/
ethnicity (white, non-white) and sex to investigate whether
the observed associations were consistent across popula-
tion strata. We adjusted for white blood cell proportions
estimated from blood reference panel [22, 23] and com-
pared the effect estimates with the PCA-based ReFACTor
method. We restricted the cord blood analysis to the 217
mother-child pairs who had DNA methylation measures
at birth and mid-childhood to examine whether the dis-
crepancy we observe between the cord blood analysis and
the life course analysis were driven by a shift in partici-
pants’ characteristics. We conducted a concurrent analysis
among the 210 mother-child pairs who had DNA methy-
lation measures only during mid-childhood and compared
results with the postnatal term in the life course analysis.
Further, we plotted DNA methylation levels of our top as-
sociations at three different time points—birth, early
childhood, and mid-childhood (N = 56)—to graphically il-
lustrate the change in methylation over time. We also
plotted the range of epigenome-wide significant methyla-
tion sites identified from the cord blood analysis and the
life course analysis.
To investigate the genetic control of methylation for
associated CpG sites, we leveraged information from a
large-scale genome-wide DNA methylation quantitative
trait loci (QTL) analysis of 1000 mother-child pairs to
examine whether the differentially methylated sites iden-
tified were partly driven by genetic variation (http://
www.mqtldb.org/) [24]. The genetic influences on DNA
methylation were studied across five different time
points in blood in this reference library: maternal [preg-
nancy, middle-age]; child [at birth, childhood, adoles-
cence]. We focused our mQTL comparisons on the cis
position (i.e., a genetic variant within ± 500Kb of a
methylation locus) measured from cord blood and per-
ipheral blood in childhood. We only considered SNPs
with MAF ≥ 5%.
Results
Participants’ characteristics
Two-hundred and forty-two children had information on
cord blood DNA methylation measurements and mid-
Peng et al. Clinical Epigenetics  (2018) 10:55 Page 5 of 14
childhood total serum IgE measurements (Table 1). Partic-
ipants included in the current analysis did not differ sub-
stantially from the overall Project Viva study population
who had serum IgE measures (Additional file 1: Table S1).
Ten percent of mothers smoked during pregnancy, and
22% were former smokers (self-reported). Thirty-seven
percent of mothers had a history of atopy (which includes
asthma, eczema, and hay fever). One hundred and sixty-
one children (67%) were white and 117 (48%) were female.
Mean ± SD age at blood draw at mid-childhood was 7.8 ±
0.7 years. Total serum IgE levels showed a right-skewed
distribution, with a mean ± SD of 146.4 ± 310.2 kU/L. Of
the 217 children pairs who had information for both cord
blood and mid-childhood DNA methylation measure-
ments, maternal and childhood characteristics did not dif-
fer substantially from those who only had DNA
methylation measured in cord blood (Table 1).
Cord blood DNA methylation and mid-childhood IgE
association
Our epigenome-wide association identified 67 methyl-
ated CpG sites (representing 58 annotated genes) in cord
blood associated with mid-childhood total serum IgE
(FDR < 0.1) (Additional file 1: Table S2; Additional file 2:
Figure S1; Fig. 3). These associations include multiple
genes that have been implicated in immuno-regulation
(AOAH, ALOX5, DHX58, and STAM2). Methylation loci
associated with obesity (AEBP2), calcium signaling
(CAPNS1), insulin signaling (INSR, PTPRN2, RPTOR) and
vasodilation (VASP) also appeared to be epigenome-wide
significant (Additional file 1: Table S2). With an FDR
threshold of less than 0.05, 19 differentially methylated
CpG sites located at 18 annotated loci in cord blood
showed epigenome-wide significance (Table 2), most of
which were involved in cell signaling, growth, and develop-
ment. We observed minimal inflation in the epigenome-
wide association analysis accounting for the first five
ReFACTor components (Additional file 2: Figure S2).
Life course analysis
Prenatal influences
We identified 98 differentially methylated CpG sites (lo-
cated at 82 annotated genes) associated with mid-
childhood total serum IgE levels (Additional file 1: Table
Table 1 Descriptive characteristics of study participants in Project Viva with information on DNA methylation and mid-childhood IgE
Participant characteristics Cord blood DNA
methylation data (N = 242)
Mid-childhood DNA
methylation data (N = 411)
DNA methylation data at
both time points (N = 217)
Maternal characteristics
Age (years), mean ± SD 32.0 (5.6) 32.3 (5.5) 32.3 (5.4)
Smoking status, N (%)
Smoked during pregnancy 24 (10%) 41 (10%) 20 (9%)
Former smoker 53 (22%) 83 (20%) 49 (23%)
Never smoker 165 (68%) 287 (70%) 148 (68%)
College graduate, N (%)
Yes 158 (65%) 271 (66%)* 144 (66%)
No 84 (35%) 138 (34%) 73 (34%)
Atopy history
Yes 90 (37%) 163 (40%)* 80 (37%)
No 152 (63%) 246 (60%) 137 (63%)
Child characteristics
Gestational age (weeks), mean ± SD 39.7 (1.6) 39.6 (1.6) 39.7 (1.6)
Age at blood drawn (years), mean ± SD 7.8 (0.7)† 7.8 (0.7)† 7.8 (0.7)
Sex, N (%)
Female 117 (48%) 201 (49%) 105 (48%)
Male 125 (52%) 210 (51%) 112 (52%)
Race/ethnicity, N (%)
White 161 (67%) 256 (62%)† 143 (66%)
Black 42 (17%) 77 (19%) 39 (18%)
Other 39 (16%) 77 (19%) 35 (16%)
Total serum IgE level in mid-childhood, (kU/L) 146.4 (310.2) 152.1 (286.2) 142.5 (311.0)
*Number of missing = 2
†Number of missings = 1
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S3; Additional file 2: Figure S1; Fig. 3), after adjustment
for postnatal DNA methylation; 13 methylation sites
overlapped with the previous analysis (i.e., showed
epigenome-wide significance with and without the
adjustment for postnatal DNA methylation changes).
The 13 methylation sites are in proximity to/within
ATP10A, C22orf45, C7orf50, DDO, INSR, KCNIP4,
LOC100128076, MPP2, STAM2, TGIF1, TRIM27, XKR6,
and ZAR1, respectively (Additional file 1: Table S3).
When we further restrict our analysis to an FDR thresh-
old of less than 0.05, we identified 16 differentially meth-
ylated CpG sites (FDR < 0.05) located at 15 annotated
genes in cord blood associated with mid-childhood total
serum IgE levels (Table 3).
Postnatal influences (Δ-DNAm)
We performed an analysis of the change in methylation
between cord blood and mid-childhood DNA (Δ-
DNAm) and identified 395 differentially methylated sites
in 272 independent loci (FDR < 0.05) in blood associated
with mid-childhood serum IgE (Additional file 1: Table
S4). Table 3 presents the top 20 differentially methylated
sites ranked by association p value. ZFPM1, ACOT7, and
MDN1 have been previously associated with total serum
IgE measurements in school-aged children from an inde-
pendent cohort [12]. Figure 4 shows the regional plot for
ACOT7—among the FDR-significant CpG sites identi-
fied, three of them were located within / close to CpG
island of the gene body. Many of the methylation sites
we identified have been associated with asthma includ-
ing ADAM19, EPX, IL4, IL5RA, and PRG2 (Table 4).
Prenatal and postnatal influences
Twenty-two methylation sites showed epigenome-wide
significance (FDR < 0.10) for both cord blood and Δ-
DNAm (from birth to mid-childhood): including three
mitochondrial-related genes associated with the oxidative
stress pathway, namely CS, SLC25A26, and TOMM34.
With an FDR threshold of less than 0.05, we identified
seven differentially methylation sites for both cord blood
and Δ-DNAm (Table 3), which include ASCC1, OR4K1,
FAM20B, KCNH2, PVT1, ARHGAP17, and AGPAT1. In
Additional file 1: Table S10, we presented summary statis-
tics of the seven FDR-significant methylation site (FDR <
0.05). We observed higher methylation values in mid-
childhood peripheral compared to cord blood among all
seven methylation studied (i.e., a positive value for
ΔCpGi). Signs of effect estimates were in the same direc-
tion for the prenatal and the postnatal terms.
Sensitivity analysis
Our associations were robust to adjustment for current
asthma status, and we observed consistent associations
within non-whites and whites, and boys and girls (Add-
itional file 1: Table S5; Additional file 1: Table S6). Further,
adjusting for estimated cell proportions from blood, a ref-
erence panel did not alter estimates of our top associations
identified from the primary analysis (Additional file 1:
Table S7; Additional file 2: Figure S5). We observed less
genomic inflation with the ReFACTor method (Add-
itional file 2: Figures S2 and S5). Restricting the cord blood
analysis to the 217 mother-child pairs who had DNA
methylation measures at birth and mid-childhood also did
not seem to influence our effect estimates (Additional file 1:
Table S8). Among the 210 mother-child pairs who only
had DNA methylation measures in mid-childhood, we ob-
served similar effect estimates when we compared the con-
current analysis with the postnatal term of the life course
analysis (Additional file 1: Table S11). Our longitudinal
plots showed more changes in DNA methylation levels in
the first 3 years of life (Additional file 2: Figure S3a; b; c).
Even though top hits identified from the epigenome-wide
association studies tend to be at the extremes of methyla-
tion (either hyper- or hypo-methylated), we still observed a
number of methylation sites with greater range of methyla-
tion values (Additional file 2: Figure S4).
Among the differentially methylated CpG sites identi-
fied in the life course analysis, most of them were not
Fig. 3 Manhattan plots. a Association between cord blood DNA
methylation and mid-childhood total serum IgE (without—top and
with—bottom adjusting for postnatal DNA methylation changes).
b Association between changes in postnatal DNA methylation from birth
and mid-childhood IgE). Red solid line—FDR significance threshold of
less than 0.05; green/blue solid line—Bonferroni significance threshold of
less than 0.05
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associated with known genetic variants in the cis-pos-
ition (i.e., ± 500Kb) (Additional file 1: Table S9). We
identified four methylation loci with cis-mQTL including
cg19549714 (TGIF1) (childhood peripheral blood),
cg18879389 (TFF2) (cord blood and childhood periph-
eral blood), and cg24576940 (KCNH2) (cord blood and
childhood peripheral blood).
Discussion
To our knowledge, this study is the first epigenome-wide
association study to conceptualize IgE-mediated allergic
response under an early-childhood life-course framework
using longitudinal methylation measured from birth to
mid-childhood. Our data show that differential methyla-
tion patterns in cord blood are associated with total serum
IgE levels in children. A number of associated cord blood
methylation signals remained epigenome-wide significant
after the adjustment for the change in methylation be-
tween cord blood and mid-childhood DNA (Δ-DNAm).
Further, change in methylation pattern from cord blood to
mid-childhood DNA (Δ-DNAm) may also be associated
with total serum IgE levels—independently or in combin-
ation with prenatal methylation marks.
It is now recognized that allergic sensitization may
occur as early as in utero [5, 6]. Factors such as genetic
predisposition [25, 26], parental atopic status [27–29], and
aspects of the intrauterine environment [30–33] including
exposures to allergens in amniotic fluid [6] may impact
the development of fetal immune responses and Th2 im-
mune responses postnatally. We identified multiple differ-
entially methylated immuno-regulatory loci in cord blood
associated with total serum IgE measured in mid-
childhood. For example, AOAH gene products—released
by neutrophils and macrophages—help to neutralize and
inactivate bacterial lipopolysaccharides (LPS); ALOX5 en-
codes for a lipoxygenase that facilitates leukotriene syn-
thesis—an important inflammatory mediator for allergic
reaction; and DHX58 is involved in antiviral signaling,
while STAM2 responds to cytokine stimulation in the JAK
kinase signaling pathway.
In addition to the findings of these immune-regulatory
genes, many other top associations have been implicated in
obesity (AEBP2) (FDR < 0.10), calcium signaling (CAPNS1)
, insulin signaling (INSR, PTPRN2, RPTOR), and vasodila-
tion (VASP). Abnormal insulin signaling often couples with
obesity and increases the risk of asthma and other child-
hood allergic disorders [34–38], while calcium signaling
has a long standing role in hyperpolarization of airway
smooth muscle cells—activation of voltage-gated calcium
channels may induce airway hyper-responsiveness—a
Table 2 Association between cord blood DNA methylation and mid-childhood IgE (FDR threshold < 0.05). Results are expressed as
the change in log(IgE) concentration per 1% increase in cord blood methylation value
CpG CHR MAPINFO Gene Estimate P value FDR
cg06226630 4 48,493,420 ZAR1 − 0.40 1.15E−07 0.013
cg03307893 15 26,108,683 ATP10A − 0.76 1.20E−07 0.013
cg13322072 7 98,784,083 KPNA7 − 0.11 1.23E−07 0.013
cg16797808 14 99,948,289 SETD3;CCNK − 0.90 3.18E−07 0.023
cg09535168 19 19,431,582 MAU2 − 1.44 3.91E−07 0.023
cg04122974 22 39,916,495 ATF4 − 3.02 4.46E−07 0.023
cg01527777 11 71,956,145 PHOX2A − 0.24 6.06E−07 0.027
cg24575275 7 1,094,737 C7orf50 − 0.29 9.23E−07 0.032
cg14920426 5 176,924,420 PDLIM7 − 1.00 1.01E−06 0.032
cg05399209 19 46,010,836 VASP − 1.33 1.03E−06 0.032
cg09507928 5 140,027,484 IK;NDUFA2 − 2.03 1.46E−06 0.040
cg24114890 14 23,834,349 EFS − 0.76 1.65E−06 0.040
cg05063806 1 36,772,417 C1orf113 − 1.26 1.79E−06 0.040
cg14167858 1 120,199,593 – 0.10 1.83E−06 0.040
cg02228675 17 40,259,724 DHX58 − 0.27 1.90E−06 0.040
cg14607755 9 139,962,279 C9orf140 − 0.49 2.25E−06 0.044
cg24630419 1 217,311,608 ESRRG − 0.41 2.49E−06 0.046
cg27212903 15 92,708,880 SLCO3A1 0.97 2.91E−06 0.048
cg14605590 9 94,900,583 LOC100128076 − 0.16 2.93E−06 0.048
Model adjusted for maternal [age at enrollment (continuous), smoking status (smoking during pregnancy/former/never), college graduate (yes/no), maternal atopy
history (yes/no)], children [child’s sex (female/male), race/ethnicity (white/black/other), gestational age (continuous), age at blood drawn (continuous)], and the
cell-type proxys using the first five ReFACTor components estimated from cord blood
Corresponding model: log(IgE) = α0 + α1CpG_cbi + α2X2 +… + αpXp + ε
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Table 3 Life course analysis—contribution of fetal and postnatal influences (FDR threshold < 0.05). For the prenatal analysis, results
are expressed as the change in log(IgE) concentration per 1% increase in cord blood methylation value. While for the postnatal
analysis, results are expressed as the change in log(IgE) concentration per 1% increase in Δ-DNAm methylation value
Prenatal influences Postnatal influences (Δ-DNAm)
CpG CHR MAPINFO Gene Estimate P value FDR Estimate P value FDR
Life course analysis—prenatal influences
cg25854298 10 73,936,754 ASCC1 − 0.36 8.02E−09 0.003 − 0.40 1.80E−13 6.28E−09
cg16416603 20 57,593,014 TUBB1 0.58 5.17E−08 0.008 0.28 1.32E−04 8.24E−02
cg11848324 14 20,403,845 OR4K1 0.57 1.48E−07 0.016 0.44 3.35E−06 5.26E−03
cg19549714 18 3,447,713 TGIF1 − 2.00 2.40E−07 0.017 − 0.10 4.45E−01 9.71E−01
cg23933289 1 178,998,656 FAM20B − 0.18 2.66E−07 0.017 − 0.17 8.01E-08 2.54E−04
cg24576940 7 150,648,283 KCNH2 − 1.54 3.31E−07 0.017 − 1.66 2.95E−08 1.10E−04
cg13443997 9 139,743,586 PHPT1 − 3.39 7.11E−07 0.028 − 1.83 1.50E−03 3.32E−01
cg19954205 12 122,211,282 TMEM120B − 1.20 7.20E−07 0.028 − 0.55 1.72E−02 7.37E−01
cg01782059 1 44,715,942 ERI3 − 0.96 1.25E−06 0.033 − 0.60 4.04E−04 1.69E−01
cg02133716 8 128,981,622 PVT1 − 0.45 1.25E−06 0.033 − 0.54 2.63E−11 3.31E−07
cg06226630 4 48,493,420 ZAR1 − 0.39 1.24E−06 0.033 − 0.02 5.24E−01 9.76E−01
cg20675173 3 43,795,541 – − 1.22 1.03E−06 0.033 − 0.72 1.11E−03 2.91E−01
cg08067346 16 25,011,481 ARHGAP17 − 0.24 1.44E−06 0.035 − 0.30 2.18E−11 2.85E−07
cg09597192 6 32,141,591 AGPAT1 − 0.31 1.78E−06 0.040 − 0.28 3.70E−06 5.67E−03
cg16096766 13 52,419,714 FLJ37307 − 0.36 2.30E−06 0.048 − 0.19 2.48E−04 1.23E−01
cg00026222 1 2,144,244 – − 1.02 2.63E−06 0.049 − 0.29 9.59E−02 9.09E−01
cg24575275 7 1,094,737 C7orf50 − 0.31 2.49E−06 0.049 − 0.02 5.23E−01 9.76E−01
Life course analysis—postnatal influences (top 20 methylation sites)
cg11699125 1 6,341,327 ACOT7 − 0.10 3.29E−02 5.88E-01 − 0.25 2.81E−23 7.95E−18
cg02970679 17 56,269,818 EPX − 0.17 9.50E−04 2.86E-01 − 0.25 5.06E−23 7.95E−18
cg24491618 7 150,649,807 KCNH2 − 0.12 1.23E−03 3.05E-01 − 0.19 2.12E−16 2.22E−11
cg01614759 10 45,495,435 C10orf25 − 0.17 2.17E−03 3.46E-01 − 0.28 2.97E−16 2.33E−11
cg13054523 17 81,055,722 – − 0.30 9.45E−05 1.53E-01 −0.43 4.23E−15 2.66E−10
cg21220721 1 6,341,230 ACOT7 0.01 7.03E−01 9.51E-01 − 0.11 1.30E−14 6.81E−10
cg10065736 12 117,440,120 FBXW8 − 0.10 2.28E−02 5.53E-01 − 0.18 2.73E−14 1.23E−09
cg06558622 7 149,543,177 ZNF862 − 0.29 3.37E−05 1.02E-01 − 0.41 8.05E−14 3.16E−09
cg25854298 10 73,936,754 ASCC1 − 0.36 8.02E−09 2.52E-03 − 0.40 1.80E−13 6.28E−09
cg05300717 11 65,546,210 DKFZp761E198 0.0002 9.93E−01 9.99E-01 − 0.33 2.11E−13 6.63E−09
cg09596645 3 181,897,670 – − 0.15 2.74E−03 3.67E-01 − 0.25 5.56E−13 1.59E−08
cg19928703 13 30,143,971 SLC7A1 − 0.19 3.05E−03 3.75E-01 − 0.31 1.06E−12 2.78E−08
cg18368116 14 21,436,271 – − 0.13 2.02E−02 5.40E-01 − 0.27 1.91E−12 4.62E−08
cg20885063 17 17,939,419 ATPAF2 − 0.16 1.85E−04 1.90E-01 − 0.23 4.05E−12 9.09E−08
cg08077807 14 62,001,072 PRKCH − 0.53 7.33E−04 2.63E-01 − 0.76 4.45E−12 9.11E−08
cg07908654 13 41,631,052 – − 0.20 3.94E−06 5.14E-02 − 0.26 4.64E−12 9.11E−08
cg08940169 16 88,540,241 ZFPM1 − 0.05 1.56E−01 7.57E-01 − 0.18 6.34E−12 1.17E−07
cg18879389 21 43,771,120 TFF2 − 0.16 6.64E−04 2.58E-01 − 0.28 6.73E−12 1.17E−07
cg20263733 3 130,616,293 ATP2C1 − 0.25 4.25E−03 3.99E-01 − 0.50 7.45E−12 1.23E−07
cg02985445 7 97,908,505 – − 0.08 3.50E−02 5.94E-01 − 0.18 8.09E−12 1.27E−07
Life course analysis—prenatal and postnatal influences
cg25854298 10 73,936,754 ASCC1 − 0.36 8.02E−09 0.003 − 0.40 1.80E−13 6.28E−09
cg11848324 14 20,403,845 OR4K1 0.57 1.48E−07 0.016 0.44 3.35E−06 0.005
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fundamental property of asthma [39]. Although those
genes may not be directly involved in immuno-regulation,
alterations in these pathways during embryonic develop-
ment may increase disease susceptibility and make the
fetus more prone to the development of IgE-mediated al-
lergic responses later in life.
Leveraging the longitudinal study design of our pre-
birth cohort, we aimed to identify differentially methyl-
ated sites at birth that are associated with later allergic
response and that may or may not be modified postna-
tally using changes in the epigenome from birth to child-
hood. We identified 98 differentially methylated CpG
sites in cord blood associated with mid-childhood total
serum IgE levels, which were independent of changes in
DNA methylation postnatally. Thirteen of these methy-
lation sites overlapped with the cord blood analysis
where we did not adjust for methylation changes after
birth. The fact that methylation levels remained
epigenome-wide significant lends support to the DOHaD
hypothesis, reinforcing that embryonic development is a
vulnerable period with high degree of epigenetic plasti-
city, and exposures occurring during this period of time
may embed epigenetically and could have an effect that
persists for decades in life independent of postnatal/
childhood influences.
Exposures during early childhood play critical roles in
IgE-mediated disease onset and manifestation. We dem-
onstrated that changes in DNA methylation levels from
baseline (cord blood) until mid-childhood—potentially
an “archive” [40] of the childhood environment—were
associated with total serum IgE measures in school-aged
children. Specifically, we identified multiple methylation
loci in genes previously associated with asthma
(ADAM19, EPX, IL4, IL5RA, and PRG2) from genome-
wide and epigenome-wide association studies [10–12,
26]. Many of those methylation sites have been
previously reported in independent large adult cohorts
(EPX, IL4, IL5RA, and PRG2) [10, 11]. IL4 and IL5RA
are well-characterized cytokines responsible for Th2 cell
differentiation and effector function, ADAM19 is in-
volved in airway and vasculature remodeling, and PRG2
and EPX are both eosinophil-related proteins that play
key roles in eosinophil-related airway inflammation.
PRG2 is a major protein component of the crystalline
core of the eosinophil granule and is involved in epithe-
lial cell damage, mast cell degranulation, and macro-
phage and neutrophil activation. EPX is a key peroxidase
enzyme in the eosinophil granules, which helps to gener-
ate potent oxidizing agents directly implicated in oxida-
tive damage processes. It is not surprising that we
identified those well-established IgE-related methylation
signals in the postnatal analysis—as children are exposed
to a more diverse environment after birth including in-
creased allergen exposures. Hence, we were able to iden-
tify a large number of signals related to allergic
symptoms and disease manifestation. Moreover, most of
these genes identified in the postnatal analysis did not
overlap with the baseline signals, which suggests that the
fetal environment may not necessarily be associated with
disease manifestation; rather, it may help to direct the
development of fetal immunity and alters disease suscep-
tibility. Future research is warranted to explore whether
the identified methylation marks are on the causal path-
way linking in utero and early-life risk factors (i.e., living
in rural versus urban areas, having siblings or not, at-
tending daycare or not, antibiotic use, pets at home) and
higher total serum IgE levels.
We observed that seven methylation sites showed
epigenome-wide significance at both baseline and post-
natally (Δ-DNAm). Among these KCNH2 encodes for a
voltage-gated K+ channel, PVT1 is a candidate oncogene
and ARHGAP17 encodes for a GTPase-activating
Table 3 Life course analysis—contribution of fetal and postnatal influences (FDR threshold < 0.05). For the prenatal analysis, results
are expressed as the change in log(IgE) concentration per 1% increase in cord blood methylation value. While for the postnatal
analysis, results are expressed as the change in log(IgE) concentration per 1% increase in Δ-DNAm methylation value (Continued)
Prenatal influences Postnatal influences (Δ-DNAm)
CpG CHR MAPINFO Gene Estimate P value FDR Estimate P value FDR
cg23933289 1 178,998,656 FAM20B − 0.18 2.66E−07 0.017 − 0.17 8.01E−08 2.54E−04
cg24576940 7 150,648,283 KCNH2 − 1.54 3.31E−07 0.017 − 1.66 2.95E−08 1.10 E−04
cg02133716 8 128,981,622 PVT1 − 0.45 1.25E−06 0.033 − 0.54 2.63E−11 3.31E−07
cg08067346 16 25,011,481 ARHGAP17 − 0.24 1.44E−06 0.035 − 0.30 2.18E−11 2.85E−07
cg09597192 6 32,141,591 AGPAT1 − 0.31 1.78E−06 0.040 − 0.28 3.70E−06 0.006
Model adjusted for maternal [age at enrollment (continuous), smoking status (smoking during pregnancy/former/never), college graduate (yes/no), maternal atopy
history (yes/no)], children [child’s sex (female/male), race (white/black/other), gestational age (continuous), age at blood drawn (continuous)], and the cell-type
proxys using the first five ReFACTor components estimated from cord blood
Corresponding model: log(IgE) = β0 + β1CpG_cbi + β2ΔCpGi + β3X3 +… + βpXp + η
Life course analysis—prenatal influence: association between cord blood methylation and mid-childhood IgE independent of postnatal changes in DNA methylation,
which correspond to β1CpG_cbi
Life course analysis—postnatal influence: association between changes in postnatal DNA methylation from birth and mid-childhood IgE independent of baseline/
cord blood DNA methylation, which correspond to ΔCpGi
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protein, which participates in the Ca2+ dependent
regulation of exocytosis. With an FDR threshold less
than 0.10, we identified 22 methylation sites (15
additional); several of these genes have been implicated
in mitochondrial function (TOMM34, CS, SLC25A26).
Mitochondria are critical cellular components that
reflect and intensify oxidative stress [41]. Epigenetic
alterations in nuclear-encoded mitochondrial genes at
both time windows suggest that intrauterine and postna-
tal cellular oxidative stress may be associated with higher
total serum IgE in mid-childhood. A handful of observa-
tional studies and clinical trials have shown that mater-
nal antioxidant intake was associated with reduced
allergic symptoms in children [33, 42–47], and antioxi-
dant intake during pregnancy and early in life may po-
tentially serves as a first-line preventive regimen to avert
childhood allergy.
Since DNA methylation was measured at birth and
early and mid-childhood, it would be interesting to ex-
plore how methylation patterns change in children who
Fig. 4 Regional manhattan plot of methylation loci within ACOT7 gene in the lifecourse postnatal influence analysis (y-axis shows the raw p values).
Dotted red line—Bonferroni significance threshold of less than 0.05
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have persistent atopy versus those who transition to a non-
atopic state. We computed a two-by-two table of atopic
sensitization at early and mid-childhood. We found that
76% of children were sensitized at both time points; only
5% of children (N = 15) are no longer atopic by age 8. Such
small sample size would make any statistical inference un-
reliable. It is widely accepted that there is an age-
dependent allergic march during childhood [48–50], begin-
ning with food allergy and atopic dermatitis (infancy to
early-childhood), followed by asthma and rhinitis (early/
mid-childhood to teen) [48–50]. Since we have methylation
measurements at birth and early and mid-childhood, the
ideal phenotype to study would be food allergy [51, 52].
However, food allergy was only measured at mid-
childhood in Project Viva. A transition from early to mid-
childhood may not be the right time window to capture
subjects no longer categorized as having atopy or asthma
phenotypes. Future research is needed to identify differen-
tial methylation patterns associated with transient and per-
sistent subtypes at appropriate developmental windows.
Our study has a number of strengths including the lon-
gitudinal nature of our analyses that enabled us to
conceptualize IgE-mediated disease etiology under an
early-childhood life-course framework. We identified some
distinct and some overlapping methylation marks at birth
and postnatally that potentially reflect IgE-mediated dis-
ease sensitization, progression, and manifestation. Most of
these methylation sites identified in the life course analysis
were not associated with known genetic variants in the
cis-position (i.e., ± 500Kb), and thus were likely to be re-
lated to endogenous or exogenous exposures. Our results
were robust to the adjustment for batch, cell proportions,
and maternal atopy history. Although we did not have ex-
ternal replication for our current analysis, many of our top
findings have been previously reported in independent co-
horts (with comparable effect estimates and direction of
effect) [11, 12], suggesting that the observed associations
were robust signals and are not cohort specific.
Our study has several limitations. First, we measured
DNA methylation from heterogeneous blood cells at birth
and in mid-childhood. Different cell types often exhibits
distinct DNA methylation patterns, and if the change in
relative cell abundance also correlates with total serum IgE
measures in mid-childhood, then our observed associations
may potentially be confounded by cellular heterogeneity.
Although we adjusted for the first five PCs of ReFACTor—
a stringent way to control for cell heterogeneity—we can-
not rule out the possibility of residual confounding. Future
analysis with relevant purified cell types might help eluci-
date the immune roots for the observed associations. Sec-
ond, we do not have genetic information on mother-child
pairs. Hence, it is difficult to disentangle the influence of
genetics and the environment. Even though we studied the
genetic control of selected methylation loci using mQTL
information from an independent cohort with relatively
large sample size (N = 1000) [24], obtaining genetic
Table 4 Life course analysis— contribution of fetal and postnatal influences (FDR threshold < 0.05)—asthma pathway. For the
prenatal analysis, results are expressed as the change in log(IgE) concentration per 1% increase in cord blood methylation value.
While for the postnatal analysis, results are expressed as the change in log(IgE) concentration per 1% increase in Δ-DNAm
methylation value
Prenatal influences Postnatal influences
CpG CHR MAPINFO Gene Estimate P value FDR Estimate P value FDR
Life course analysis—postnatal influences (asthma pathway)
cg26787239 5 132,008,525 IL4 − 0.12 9.00E−02 6.91E−01 − 0.18 1.94E−05 0.020
cg01310029 3 3,152,374 IL5RA − 0.09 7.48E−02 6.73E−01 − 0.18 3.55E−06 0.005
cg02970679 17 56,269,818 EPX − 0.17 9.50E−04 2.86E−01 − 0.25 5.06E−23 7.95E−18
cg25173129 17 56,269,410 EPX − 0.16 5.73E−03 4.22E−01 − 0.22 2.59E−08 9.80E−05
cg27469152 17 56,282,313 EPX − 0.10 5.02E−02 6.32E−01 − 0.19 2.59E−07 6.53E−04
cg18421167 17 56,276,490 EPX − 0.09 2.38E−01 8.07E−01 − 0.25 1.83E−06 0.003
cg08105265 17 56,274,480 EPX − 0.04 6.46E−01 9.40E−01 − 0.22 1.55E−05 0.017
cg12819873 11 57,157,632 PRG2 − 0.12 8.55E−03 4.60E−01 − 0.23 1.21E−09 9.05E-06
cg15700636 11 57,156,050 PRG2 − 0.08 3.19E−02 5.85E−01 − 0.18 4.13E−08 1.46E−04
cg08295410 5 156,990,663 ADAM19 − 0.31 4.79E−03 4.09E−01 − 0.40 2.70E−05 0.026
Model adjusted for maternal [age at enrollment (continuous), smoking status (smoking during pregnancy/former/never), college graduate (yes/no), maternal atopy
history (yes/no)], children [child’s sex (female/male), race (white/black/other), gestational age (continuous), age at blood drawn (continuous)], and the cell-type
proxys using the first five ReFACTor components estimated from cord blood
Corresponding model: log(IgE) = β0 + β1CpG_cbi + β2ΔCpGi + β3X3 +… + βpXp + η
Life course analysis—prenatal influence: association between cord blood methylation and mid-childhood IgE independent of postnatal changes in DNA methylation,
which correspond to β1CpG_cbi;
Life course analysis—postnatal influence: association between changes in postnatal DNA methylation from birth and mid-childhood IgE independent of baseline/
cord blood DNA methylation, which correspond to ΔCpGi
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information from our own population will further eluci-
date whether the identified methylation marks reflect
genetic predisposition, the impact of the intrauterine,
postnatal and childhood environments, or an inter-
action of the two.
Conclusion
In summary, leveraging the epigenetic plasticity from
the prenatal period till childhood, our work identified
differentially methylated patterns—in cord blood, as well
as in changes in methylation levels from cord blood to
mid-childhood DNA—associated with mid-childhood
IgE. Several cord blood methylation marks associated
with IgE that were independently of postnatal change in
methylation levels. Further, change in methylation pat-
tern from cord blood to mid-childhood DNA were asso-
ciated with IgE—independently or in combination with
cord blood methylation marks. Our study provides evi-
dence for the epigenetic regulatory mechanism of IgE-
mediated diseases and offers a scientific basis to pro-
mote early prevention of IgE-mediated diseases.
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